Results 21 to 30 of about 148,724 (217)
Distinct activation mechanisms regulate subtype selectivity of Cannabinoid receptors
Design of cannabinergic subtype selective ligands is challenging because of high sequence and structural similarities of cannabinoid receptors (CB1 and CB2).
Soumajit Dutta, Diwakar Shukla
doaj +1 more source
Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. [PDF]
OBJECTIVE Blockade of the CB1 receptor is one of the promising strategies for the treatment of obesity. Although antagonists suppress food intake and reduce body weight, the role of central versus peripheral CB1 activation on weight loss and related ...
Nogueiras, Ruben +27 more
core +3 more sources
Cannabinoid receptors 1 and 2 (CB1 and CB2, respectively) play an important role in maintaining the integrity of the blood–brain barrier (BBB). On the other hand, BBB dysfunction is a common feature in drug-resistant epilepsy.
María de los Ángeles Nuñez-Lumbreras +12 more
doaj +1 more source
Agonists of CB1 and NMDA receptors decrease the toxic effect of organophosphorus compound paraoxon on PC12 cells [PDF]
Pharmacological studies allow to suggest that activation of cannabinoid type 1 receptors (CB1) have a neuroprotective role against toxicity induced by organophosphate agents, but the exact mechanisms of this effect as well as interaction with receptors ...
F. Salem +4 more
doaj +1 more source
Ontogeny of Endocannabinoid Modulation of Neuromuscular Transmission: Contribution of Postsynaptic Nicotinic Receptors and Butyrylcholinesterase-Sensitive Mechanisms. [PDF]
Endocannabinoid receptors of the CB1 subtype are the most abundant G-protein-coupled receptors in the central nervous system, where they strongly regulate neurotransmitter release.
Nevsky E +6 more
europepmc +2 more sources
Neutral antagonists of GPCRs remain relatively rare—indeed, a large majority of GPCR antagonists are actually inverse agonists. The synthetic cannabinoid receptor agonist (SCRA) EG‐018 was recently reported as a low efficacy cannabinoid receptor agonist.
David B. Finlay +9 more
doaj +1 more source
Background This study investigated changes in the expression of cannabinoid (CB) receptors and the effects of CB1 and CB2 agonists on detrusor overactivity (DO) associated with bladder outlet obstruction (BOO) in rats.
Sung Dae Kim +2 more
doaj +1 more source
Impaired Excitatory Neurotransmission in the Urinary Bladder from the Obese Zucker Rat: Role of Cannabinoid Receptors. [PDF]
Metabolic syndrome (MS) is a known risk factor for lower urinary tract symptoms. This study investigates whether functional and expression changes of cannabinoid CB1 and CB2 receptors are involved in the bladder dysfunction in an obese rat model with ...
Igor Blaha +10 more
doaj +1 more source
Voltage dependence of the cannabinoid CB1 receptor
Cannabinoids produce their characteristic effects mainly by binding to two types of G-protein coupled receptors (GPCRs), the CB1 and CB2 cannabinoid receptors.
Esty Goldberger +2 more
doaj +1 more source
Cannabinoid (CB) receptor agonists are of growing interest as targets for anti-seizure therapies. Here we examined the effect of systemic administration of the CB receptor agonist WIN 55,212-2 (WIN) against audiogenic seizures (AGSs) in the Genetically ...
Victor R. Santos +10 more
doaj +1 more source

